TELA Bio, Inc. (TELA)

Market Cap	31.39M -67.2%
Revenue (ttm)	77.06M +12.2%
Net Income	-39.00M
EPS	-0.89
Shares Out	40.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,852
Open	0.7550
Previous Close	0.7500
Day's Range	0.7471 - 0.7905
52-Week Range	0.6671 - 2.4780
Beta	0.89
Analysts	Strong Buy
Price Target	3.31 (+325.4%)
Earnings Date	May 7, 2026

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA
• Website: https://www.telabio.com

Financial Performance

In 2024, TELA Bio's revenue was $69.30 million, an increase of 18.56% compared to the previous year's $58.45 million. Losses were -$37.84 million, -18.91% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price target is $3.31, which is an increase of 325.40% from the latest price.

Price Target

$3.31

(325.40% upside)

Analyst Consensus: Strong Buy